In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 33-37

  Kilic, S ^a   Dizbay, M ^b   Cabadak, H ^c  

^a Refik Saydam Hygiene Center   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c TYIH   (Turkey)

Author keywords

Brucella; E test; Susceptibility; Tetracycline; quinolones; Tigecycline

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; TETRACYCLINE; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BRUCELLA MELITENSIS; BRUCELLOSIS; DRUG ACTIVITY; EPSILOMETER TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 41149176150     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.33     Document Type: Article

References (32)

1. Joint Food and Agriculture Organization/World Health Organization. FAO-WHO Expert Committee on brucellosis (sixth report). WHO Technical Report Series No. 740. Geneva: World Health Organisation; 1986: 56-57.
2. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. brucellosis. N Engl J Med 2005; 352: 2325-36.
3. Pappas G, Solera J, Akritidis N et al. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005; 26: 101-5.
4. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997; 53: 245-256.
5. Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270-2277.
6. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006;43:518-4.
7. George A. Pankey. Tigecycline. J Antimicrob Chemother 2005; 56: 470-480.
8. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-744.
9. Livermore DM. Tigecycline: What is it, and where should it be used. J Antimicrob Chemother 2005; 56: 611-614.
10. Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 2007; 39 (5): 432-4.
11. Esmon, LSF, Crane JP, Blowers A. Effect of ciprofloxacin on intracellular organisms, in vitro and in vivo studies. J Antimicrob Chemother 1986; 18 Suppl D: 43-48.
12. Falagas ME, Bliziotis Ioannis A. Quinolones for Treatment of Human brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies. Antimicrob Agents Chemother 2006; 50: 22-33.
13. Pappas G, Christou L, Akritidis N, Tsianos EV. Quinolones for brucellosis: Treating Old Diseases with New Drugs. Clin Microbiol Infect 2006; 12(9): 823-25.
14. Corbel MJ. Microbiological aspects. In: Madkour MM, ed. Madkour's brucellosis. 2th ed. Berlin Heidelberg New York: Springer-Verlag. 2001: 51-64.
15. Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis Laboratory. Paris: Institut National de la recherche Agronomique (INRA). 1988: 34-61.
16. Gur D, Kocagoz S, Akova M. Comparison of E-test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 2337.
17. King A. Recommendations for susceptibility tests on fastidious organisms and those requirind special handling. J Antimicrob Chemother. 2001; 48 Suppl S1: 77-80.
18. Madkour MM. Treatment. In: Madkour MM, ed. Madkour's brucellosis. 2th Edition Berlin Heidelberg New York: Springer-Verlag. 2001: 241-61.
19. Ariza J, Bocsh J, Gudiol F, Linares J, Viladrich PF, Martin R. Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemoter 1986; 30: 958-60.
20. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1991; 13: 523-524.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Sixteenth informational supplement. CLSI document M 100-S16, Wayne, PA, USA. 2006.
22. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E-test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43: 140-3.
23. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405-7.
24. Kose S, Kilic S, Ozbel Y. Identification of Brucella species isolated from proven brucellosis Patient in Izmir, Turkey. J Basic Microbiol 2005; 45: 323-7.
25. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5: 24.
26. Bodur H, Balaban N, Aksaray S et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337-8.
27. Yamazhan T, Aydemir S, Tunger A, Serter D, Gokengin D. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean Region in Turkey. Med Princ Pract 2005; 14: 413-6.
28. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201-9.
29. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ. CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1875-81.
30. Kocagoz S, Akova M, Altun B, Gur D, Hascelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002; 8: 240-242.
31. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new Fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 194-95.
32. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scan J Infect Dis 2004; 36: 636-38.